The biopharma industry is facing increasing pressure from macro issues like the lasting impact from the pandemic and debate over drug pricing. In a recent interview, Novartis AG's Pharmaceuticals president Marie-France Tschudin weighed in on US drug price reform, competitive rebating and how COVID-19 has changed the way the industry operates, as well as on some of the long-term growth opportunities for the company's anchor brands.
(Also see "Novartis’s Tschudin On Launches, Drug Pricing And Lasting COVID Impacts" - Scrip, 22 September, 2021.)
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?